Clinical trials: Systemic Scleroderma, open to volunteers
Systemic Sclerosis (SSc), Pulmonary Arterial Hypertension (PAH)
Home-Based Clinical Management of Cardiac Complications in Systemic Sclerosis
The goal of this observational pilot trial is to evaluate the feasibility of home monitoring for patients with systemic sclerosis-associated pulmonary arterial hypertension (SSc-PAH).
- Conditions
- Systemic Sclerosis (SSc), Pulmonary Arterial Hypertension (PAH), Home Monitoring Follow-up
- Trial name
- Nor-SScCare (NCT06865118)
- Where
- Norway
- Volunteers
- 20 people
- Sponsor
- Oslo University Hospital
Systemic Sclerosis, Interstitial Lung Disease
Study of the Efficacy of Nintedanib+Tocilizumab in Patients With Systemic Sclerosis and Interstitial Lung Disease
The study includes adult patients with systemic sclerosis (SSc) with interstitial lung disease (ILD) to evaluate the efficacy and safety of nintedanib plus tocilizumab combination therapy compared to standard therapy…
- Trial name
- NINTOC-TU (NCT06297096)
- Testing
- Tocilizumab, Nintedanib, Standard therapy
- Where
- Poland
- Volunteers
- 86 people
- Sponsor
- National Institute of Geriatrics, Rheumatology and Rehabilitation, Poland
Systemic Sclerosis
Safety and Efficacy of Itacitinib in Adults With Systemic Sclerosis
The purpose of this study is to determine whether itacitinib is safe and effective in the treatment of systemic sclerosis in adults.
- Trial name
- SCLERITA (NCT04789850)
- Testing
- Itacitinib
- Where
- 46 sites in France
- Volunteers
- 74 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Scleroderma
Transcriptomic Study of Cutaneous Fibroblasts in Scleroderma
Scleroderma is a complex connective tissue disease involving three interconnected pathophysiological axes: vascular hyperactivity and remodelling, immune system dysfunction and over-activation of fibroblasts at the origin of the…
- Trial name
- TRANSCLERO (NCT07256418)
- Testing
- Skin samples, Analysis of fibroblasts
- Where
- France
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire Dijon
Systemic Sclerosis
A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis
Nerandomilast is being developed to help people with systemic sclerosis by potentially improving symptoms and slowing disease progression.
- Trial name
- VERANDA™-SSc (NCT07497087)
- Testing
- Nerandomilast formulation 1, Nerandomilast formulation 2
- Where
- 248 sites in United States, Argentina and 43 more
- Volunteers
- 448 people
- Sponsor
- Boehringer Ingelheim
Systemic Lupus Erythematosus (SLE), Sjogren's Syndrome
Universal CAR-T Cells (BRL-301) in Relapse or Refractory Autoimmune Diseases
This is an investigator initiated trial to assess the efficacy and safety of BRL-301 in the relapse or refractory autoimmune diseases of China.
- Conditions
- Systemic Lupus Erythematosus (SLE), Sjogren's Syndrome, Systemic Sclerosis, Inflammatory Myopathy
- Trial name
- NCT05859997
- Testing
- BRL-301
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Bioray Laboratories
Healthy, Idiopathic Inflammatory Myopathies
A Phase 1 Open-label Study to Evaluate Safety in Healthy Participants and Participants With Autoimmune Diseases
The purpose of this study is to determine the safety and tolerability of XmAb657 in healthy participants and participants with autoimmune diseases.
- Conditions
- Healthy, Idiopathic Inflammatory Myopathies, Systemic Sclerosis, Sjögren's Disease
- Trial name
- NCT07284797
- Testing
- XmAb657
- Where
- Australia
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Xencor, Inc.
Systemic Lupus Erythematosus, Rheumatoid Arthritis
Early Clinical Study of UTAA91 Injection for the Treatment of Relapsed/Refractory Autoimmune Diseases
This clinical trial is designed as a single - arm, open - label, single - center, investigator - initiated early - phase clinical study.
- Conditions
- Systemic Lupus Erythematosus, Rheumatoid Arthritis, Dry Syndrome, Idiopathic Inflammatory Myopathies
- Trial name
- NCT06970951
- Testing
- UTAA91 injection
- Where
- China
- Volunteers
- 15 people
- Sponsor
- PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Systemic Sclerosis, Pulmonary Arterial Hypertension
Extracellular Vesicle Dynamics Predicting Vascular Complications and Treatment Response in Systemic Sclerosis
Systemic sclerosis is a multisystem autoimmune disease characterized by vascular dysfunction, immune dysregulation, and progressive tissue fibrosis.
- Conditions
- Systemic Sclerosis, Pulmonary Arterial Hypertension, Digital Ulcers, Vascular Complications
- Trial name
- EVOLVE-SSc (NCT07717060)
- Testing
- Blood sampling, nailfold capillaroscopy
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Scleroderma (Limited and Diffuse)
Pathogenic Mechanisms Involved in the Initiation and Progression of Systemic Sclerosis
Identify rare variants in candidate genes and pathways identified in familial SSc, in patients with sporadic SSc. Perform (spatial) transcriptomic and proteomic analyses of affected skin from patients with and without cutaneous…
- Trial name
- NCT07015060
- Testing
- cutaneous biospy
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Université Catholique de Louvain
Rare Disorders, Undiagnosed Disorders
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
The Coordination of Rare Diseases at Sanford (CoRDS) is an international patient registry that serves as a centralized resource for rare disease research.
- Conditions
- Rare Disorders, Undiagnosed Disorders, Disorders of Unknown Prevalence, Cornelia De Lange Syndrome
- Trial name
- CoRDS (NCT01793168)
- Where
- United States
- Volunteers
- 20,000 people
- Sponsor
- Sanford Health
Systemic Sclerosis (SSc)
The Apollo Device in Systemic Sclerosis for the Management of fatiguE, Raynaud Phenomenon and qualiTy of Life
The purpose of this study it to test the efficacy of a wearable device to improve symptom management and maximize qualify of life in systemic Sclerosis (SSc) patients in a randomized trial.
- Trial name
- ASScERT-QoL (NCT06675344)
- Testing
- Apollo Neuro Device
- Where
- 4 sites in United States
- Volunteers
- 160 people
- Sponsor
- Robyn T. Domsic, MD, MPH
Interstitial Lung Disease Due to Systemic Disease, Scleroderma
Platform Clinical Study for Conquering Scleroderma
The goal of this clinical trial is to test efficacy of different investigational products (IPs) compared with placebo on the change from baseline to the end of the treatment period at Week 52 in lung capacity in participants with…
- Trial name
- CONQUEST (NCT06195072)
- Testing
- Amlitelimab, BI 1015550 (Nerandomilast)
- Where
- 34 sites in United States
- Volunteers
- 400 people
- Sponsor
- Scleroderma Research Foundation, Inc.
Scleroderma, Sclerodactyly
Hyaluronidase Injections for Sclerodactyly in Patients With Scleroderma
Systemic sclerosis can cause the skin of the fingers to become thick and tight, a condition called sclerodactyly. This can make it difficult to bend, straighten, and use the fingers.
- Conditions
- Scleroderma, Sclerodactyly, Systemic Sclerosis
- Trial name
- NCT07916324
- Testing
- hyaluronidase
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Stanford University
Eosinophilic Fasciitis
EFESO: Study on Juvenile Onset Eosinophilic Fasciitis
Eosinophilic fasciitis is a connective tissue disorder characterized by inflammation of the muscle fasciae, which is very rare in children.
- Trial name
- NCT07348263
- Where
- 15 sites in United States, Croatia and 9 more
- Volunteers
- 20 people
- Sponsor
- Meyer Children's Hospital IRCCS
Systemic Sclerosis (SSc)
A Study of Cizutamig in Systemic Sclerosis
The purpose of this study is to assess the safety, tolerability, PK, PD, immunogenicity, and preliminary clinical activity of cizutamig in patients with SSc.
- Trial name
- NCT07158996
- Testing
- Biological: cizutamig
- Volunteers
- 10 people
- Sponsor
- Ruijin Hospital
Autoimmune Bullous Dermatosis, Dysimmune Dermatological Diseases
Clinico-biological Collection of Autoimmune, Dysimmune or Auto-inflammatory Dermatological Diseases
The aim of this project is to start a biological and clinical collection of patients presenting autoimmune, dysimmune or auto-inflammatory dermatological diseases.
- Conditions
- Autoimmune Bullous Dermatosis, Dysimmune Dermatological Diseases, Auto-inflammatory Dermatological Diseases, Skin Diseases
- Trial name
- TekAPo (NCT06387654)
- Testing
- Blood sampling, Remainders of samples taken as part of the treatment
- Where
- France
- Volunteers
- 800 people
- Sponsor
- University Hospital, Toulouse
Atopic Dermatitis, Psoriasis
Identification of Cutaneous and Blood Biomarkers Predictive of Response to Systemic Treatments During Chronic Inflammatory Skin Diseases
Chronic inflammatory skin diseases constitute a heterogeneous group of pathologies. They affect the skin but also other organs (joints, lungs, muscles, etc.). Their prognosis and response to treatments is extremely variable.
- Conditions
- Atopic Dermatitis, Psoriasis, Hidradenitis Suppurativa, Lichen Planus
- Trial name
- ImmuneSkinBank (NCT06599411)
- Testing
- Sampling
- Where
- France
- Volunteers
- 830 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Systemic Sclerosis (SSc), Systemic Sclerosis (Scleroderma)
Cultural Adaptation, Validity, and Reliability of the Turkish Version of The PASTUL Questionnaire
The Patient Self-Assessment of Skin Thickness in Upper Limb (PASTUL) questionnaire was developed to enable patients to assess skin thickness in systemic sclerosis (SSc) physically and has been validated for reliability and…
- Conditions
- Systemic Sclerosis (SSc), Systemic Sclerosis (Scleroderma), Scleroderma (Limited and Diffuse), Patient Perspective
- Trial name
- NCT07182968
- Testing
- Questionnaire study
- Where
- Turkey (Türkiye)
- Volunteers
- 50 people
- Sponsor
- Hacettepe University
Systemic Sclerosis (SSc)
Systemic Sclerosis DIet for GastrointESTinal Symptoms
This research will evaluate the effect of diets on bloating/distention, assess changes in abdominal pain, and overall gastrointestinal symptom burden in Systemic Sclerosis.
- Trial name
- DIGEST (NCT07402226)
- Testing
- Diet 1: Restriction of fermentable carbohydrates, Diet 2: Elimination of foods harmful to gut barrier and microbiome, Diet 3: Regular meal patterns, soluble fiber, and portion control
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- University of Michigan